Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Pheochromocytoma 1Paraganglioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Advanced Neuroendocrine Neoplasm 1

Interventions

Etoposide 3Carboplatin 3atezolizumab 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1Cisplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Extensive Stage Small Cell Lung Cancer × lutetium Lu 177 dotatate × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡